Company record

Atlas Bio

Uses a foundation AI model of human biology to run in silico clinical trials. atlas.bio

Funding

Of the 97 seed rounds with exactly stated amounts in dollars on Presspool's weekly rosters since September 21, 2026, Atlas Bio's $10 million is the joint 28th largest; their median is $7.4 million.

Whether AI names Atlas Bio

A company counts when an AI answer names it or cites its website. Answers vary from run to run, so each count is a dated sample.

Related records

Closest rounds in the roster for October 26–31, 2026: ALLOX (US$10.5 million seed, October 29, 2026), Northstar Security ($7 million seed, October 28, 2026), Lette ($6.5 million seed, October 26, 2026), Ravical ($17 million seed, October 29, 2026), Nagare Labs ($5 million seed, October 26, 2026), Machenta ($40 million seed, October 27, 2026).

Creandum, which led this round, also led Ancep ($8.5m, round type not disclosed, November 10, 2026), Machenta ($40 million seed, October 27, 2026), Turba Labs ($52 million Seed and Series A, October 6, 2026) and hosted·ai ($19M Seed, March 19, 2026). It is also named as an investor in Causa Prima ($20 million Seed, October 13, 2026) and Scarlet ($50 million Series B, October 12, 2026). 1 more of its rounds is on its page.

Sources

Every fact on this page links its source. Corrections need a public source: see Contact.